Evidence map›Paper›PMID 34772811›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2021

Vaccine-elicited CD4 T cells prevent the deletion of antiviral B cells in chronic infection.

Kerstin Narr, Yusuf I Ertuna, Benedict Fallet, Karen Cornille, Mirela Dimitrova, Anna-Friederike Marx, Katrin Martin, Tiago Abreu Mota, Marco Künzli, David Schreiner and 9 more

Open access · greenAbstract read
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.5field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Orf virus-based vectors induce potent germinal center B cell, Tfh cell, and CD8Molecular therapy : the journal of the American Society of Gene Therapy · 2025
    Article
  3. Central tolerance shapes the neutralizing B cell repertoire against a persisting virus in its natural host.Proceedings of the National Academy of Sciences of the United States of America · 2024
    Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 4 institutions in 2 countries.

Kerstin NarrDivision of Experimental Virology, Department of Biomedicine, University of Basel, 4003 Basel, Switzerland.ORCID 0000-0002-0513-7271
Yusuf I ErtunaDivision of Experimental Virology, Department of Biomedicine, University of Basel, 4003 Basel, Switzerland.
Benedict FalletDivision of Experimental Virology, Department of Biomedicine, University of Basel, 4003 Basel, Switzerland.ORCID 0000-0003-1530-6355
Karen CornilleDivision of Experimental Virology, Department of Biomedicine, University of Basel, 4003 Basel, Switzerland.
Mirela DimitrovaDivision of Experimental Virology, Department of Biomedicine, University of Basel, 4003 Basel, Switzerland.
Anna-Friederike MarxDivision of Experimental Virology, Department of Biomedicine, University of Basel, 4003 Basel, Switzerland.
Katrin MartinDivision of Experimental Virology, Department of Biomedicine, University of Basel, 4003 Basel, Switzerland.
Tiago Abreu MotaDivision of Experimental Virology, Department of Biomedicine, University of Basel, 4003 Basel, Switzerland.
Marco KünzliImmune Cell Biology Laboratory, Department of Biomedicine, University Hospital Basel, 4031 Basel, Switzerland.ORCID 0000-0001-7699-779X
David SchreinerImmune Cell Biology Laboratory, Department of Biomedicine, University Hospital Basel, 4031 Basel, Switzerland.ORCID 0000-0003-0324-2526
Tobias M BrunnerExperimental Immunology and Osteoarthritis Research, Department of Rheumatology and Clinical Immunology, Charité-Universitätsmedizin Berlin, 10117 Berlin, Germany.ORCID 0000-0002-5279-2391
Mario KreutzfeldtDivision of Clinical Pathology, Geneva University Hospital, 1211 Geneva, Switzerland.ORCID 0000-0003-0335-2733
Ingrid WagnerDepartment of Pathology and Immunology, Geneva Faculty of Medicine, Geneva University Hospital, 1211 Geneva, Switzerland.
Florian GeierDepartment of Biomedicine, Bioinformatics Core Facility, University Hospital Basel, 4031 Basel, Switzerland.
Lukas BestmannMedisupport, Medizinische Laboratorien Dr. Toggweiler, 8304 Wallisellen, Switzerland.ORCID 0000-0002-6444-9419
Max LöhningExperimental Immunology and Osteoarthritis Research, Department of Rheumatology and Clinical Immunology, Charité-Universitätsmedizin Berlin, 10117 Berlin, Germany.ORCID 0000-0001-6382-7281
Doron MerklerDivision of Clinical Pathology, Geneva University Hospital, 1211 Geneva, Switzerland.
Carolyn G KingImmune Cell Biology Laboratory, Department of Biomedicine, University Hospital Basel, 4031 Basel, Switzerland.
Daniel D PinschewerDivision of Experimental Virology, Department of Biomedicine, University of Basel, 4003 Basel, Switzerland; Daniel.Pinschewer@unibas.ch.ORCID 0000-0002-1594-3189
University of Basel · CHUniversity Hospital of Basel · CHUniversity Hospital of Geneva · CHGerman Rheumatism Research Centre · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chronic viral infections subvert protective B cell immunity. An early type I interferon (IFN-I)-driven bias to short-lived plasmablast differentiation leads to clonal deletion, so-called "decimation," of antiviral memory B cells. Therefore, prophylactic countermeasures against decimation remain an unmet need. We show that vaccination-induced CD4 T cells prevented the decimation of naïve and memory B cells in chronically lymphocytic choriomeningitis virus (LCMV)-infected mice. Although these B cell responses were largely T independent when IFN-I was blocked, preexisting T help assured their sustainability under conditions of IFN-I-driven inflammation by instructing a germinal center B cell transcriptional program. Prevention of decimation depended on T cell-intrinsic Bcl6 and Tfh progeny formation. Antigen presentation by B cells, interactions with antigen-specific T helper cells, and costimulation by CD40 and ICOS were also required. Importantly, B cell-mediated virus control averted Th1-driven immunopathology in LCMV-challenged animals with preexisting CD4 T cell immunity. Our findings show that vaccination-induced Tfh cells represent a cornerstone of effective B cell immunity to chronic virus challenge, pointing the way toward more effective B cell-based vaccination against persistent viral diseases.

Indexed as

AnimalsAntibodies, ViralAntigen PresentationAntiviral AgentsB-LymphocytesCD4-Positive T-LymphocytesCells, CulturedGerminal CenterInflammationLymphocytic ChoriomeningitisLymphocytic choriomeningitis virusMemory B CellsMicePersistent InfectionProto-Oncogene Proteins c-bcl-6Th1 CellsAntibodies, ViralAntiviral AgentsProto-Oncogene Proteins c-bcl-6VaccinesB cell decimationchronic viral infectioninterferonT cell helpT follicular helper cells

Identifiers

PMID34772811
PMCPMC8694065
OpenAlexW3213031072

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.